Patrick M. Forde
Impact in
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Lung Cancer Research Studies
- Cancer Research top 0.5%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 110
- Cancer Immunotherapy and Biomarkers 94
- CAR-T cell therapy research 15
- Lung Cancer Research Studies 14
-
- Lung Cancer Treatments and Mutations 48
- Lung Cancer Diagnosis and Treatment 21
- Occupational and environmental lung diseases 11
- Co-authors
- Julie Renee Brahmer (50 shared papers)Jarushka Naidoo (30 shared papers)Evan J. Lipson (12 shared papers)Kristen Ashley Marrone (26 shared papers)David S. Ettinger (17 shared papers)Suzanne Louise Topalian (6 shared papers)Ronan Joseph Kelly (11 shared papers)Leisha A. Emens (2 shared papers)
- Journals
- Journal of Thoracic Oncology (17 papers)Journal for ImmunoTherapy of Cancer (15 papers)Clinical Cancer Research (11 papers)Lung Cancer (7 papers)The Oncologist (7 papers)
- Partner nations
- United StatesIrelandCanada
In The Last Decade
Patrick M. Forde
179 papers receiving 14.1k citations
Patrick M. Forde's Hit Papers
Peers
Comparison fields: 5 of 134
- Oncology 7.6k
- Cancer Research 2.3k
- Pulmonary and Respiratory Medicine 4.4k
- Immunology 2.7k
- Genetics 413
Countries citing papers authored by Patrick M. Forde
This map shows the geographic impact of Patrick M. Forde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick M. Forde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick M. Forde more than expected).
Fields of papers citing papers by Patrick M. Forde
This network shows the impact of papers produced by Patrick M. Forde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick M. Forde. The network helps show where Patrick M. Forde may publish in the future.
Co-authors
The 25 scholars most cited alongside Patrick M. Forde, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 185 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Neoadjuvant PD-1 Blockade in Resectable Lung Cancer Hit paper breakdown → | 2018 | 1647 |
| 2 | Genome-wide cell-free DNA fragmentation in patients with cancer Hit paper breakdown → | 2019 | 1018 |
| 3 | Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer Hit paper breakdown → | 2016 | 759 |
| 4 | Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC) Hit paper breakdown → | 2018 | 438 |
| 5 | Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers Hit paper breakdown → | 2021 | 387 |
| 6 | Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer Hit paper breakdown → | 2020 | 376 |
| 7 | 2018 | 343 | |
| 8 | Detection and characterization of lung cancer using cell-free DNA fragmentomes Hit paper breakdown → | 2021 | 324 |
| 9 | Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations Hit paper breakdown → | 2016 | 314 |
| 10 | Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors Hit paper breakdown → | 2021 | 298 |
| 11 | 2017 | 275 | |
| 12 | 2020 | 273 | |
| 13 | 2018 | 271 | |
| 14 | Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels Hit paper breakdown → | 2022 | 269 |
| 15 | 2015 | 265 | |
| 16 | PD-1 Blockade in Anaplastic Thyroid Carcinoma Hit paper breakdown → | 2020 | 261 |
| 17 | 2018 | 230 | |
| 18 | Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy Hit paper breakdown → | 2023 | 223 |
| 19 | 2012 | 173 | |
| 20 | 2019 | 173 |
About Patrick M. Forde
Patrick M. Forde is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Immunology and Genetics, having authored 185 papers that have together received 14.3k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (94 papers), Lung Cancer Treatments and Mutations (48 papers), Cancer Genomics and Diagnostics (26 papers), Lung Cancer Diagnosis and Treatment (21 papers), Immunotherapy and Immune Responses (16 papers), CAR-T cell therapy research (15 papers), Lung Cancer Research Studies (14 papers) and Occupational and environmental lung diseases (11 papers). The work is most often cited by research in Oncology (7.6k citations), Cancer Research (2.3k citations), Pulmonary and Respiratory Medicine (4.4k citations), Immunology (2.7k citations) and Genetics (413 citations). Patrick M. Forde has collaborated with scholars based in United States, Ireland and Canada. Frequent co-authors include Julie Renee Brahmer, Jarushka Naidoo, Evan J. Lipson, Kristen Ashley Marrone, David S. Ettinger, Suzanne Louise Topalian, Ronan Joseph Kelly, Leisha A. Emens, Drew Pardoll and Janis Marie Taube. Their work appears in journals such as Journal of Thoracic Oncology, Journal for ImmunoTherapy of Cancer, Clinical Cancer Research, Lung Cancer and The Oncologist.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.